Timing correction: Align Technology is scheduled to report today, Wednesday, July 29, 2026, after the market closes—not tomorrow. Results are due at 4:00 p.m. ET, followed by the call at 4:30 p.m. ET. (investor.aligntech.com)
This report is less about whether Align can meet its relatively narrow Q2 revenue range and more about the quality and durability of its recovery.
Investors should focus on four questions:
The setup is balanced. Q1 was strong, the Q2 comparison is relatively easy, and full-year revenue guidance appears achievable. However, reported growth has benefited materially from currency, U.S. consumer demand remains uncertain, and the full-year margin target requires a substantial second-half step-up.
| Metric | Q1 2026 actual | Q2 2026 company outlook / expectations |
|---|---|---|
| Revenue | $1.040B | $1.040B–$1.060B |
| Revenue growth | +6.2% YoY | Approximately +3% to +5% |
| Clear-aligner shipments | 685.7K | Up sequentially and YoY |
| Clear-aligner ASP | $1,250 per shipment | Approximately flat sequentially and YoY |
| Systems & Services revenue | $184.1M | Up sequentially |
| GAAP operating margin | 13.6% | Approximately 16.4% |
| Non-GAAP operating margin | 21.5% | Approximately 21.5% |
| Street revenue | — | Roughly $1.05B–$1.06B |
| Street adjusted EPS | — | Roughly $2.49–$2.62, depending on provider |
Public estimate aggregators place revenue near the upper half of management’s range, while adjusted EPS estimates vary because of differing methodologies. Align itself did not provide explicit Q2 EPS guidance. (benzinga.com)
Q1 clear-aligner shipments reached a record 685.7 thousand, up 6.7% year over year and 1.3% sequentially. International markets grew at double-digit rates, while North America was described as stable. Shipments to orthodontists increased 7.4%, versus 5.6% growth among GP dentists. (sec.gov)
For Q2, management guided shipments to increase both sequentially and year over year. That means volume should exceed Q1’s 685.7 thousand and compare favorably with only 644.4 thousand in Q2 2025, when patient conversion was weak and clear-aligner volume grew just 0.3%. (investor.aligntech.com)
What would constitute a good result:
A volume beat driven by international markets and DSOs would still be positive, but the higher-quality outcome would include evidence that independent U.S. practices and GP dentists are converting more consultations into paid case starts.
Align’s international business has been carrying the growth profile. In Q1, EMEA, APAC and Latin America all delivered double-digit volume growth, while North America remained modestly down but stable.
Management attributed the U.S. weakness primarily to macroeconomic conditions rather than a material change in competition. That explanation is plausible because Invisalign is generally an elective, consumer-funded procedure. However, investors should not dismiss competitive and product-mix issues: practices offering both clear aligners and traditional braces may favor lower-cost wires and brackets when patient affordability becomes more important.
The call should clarify:
A simple “North America remained stable” would probably be adequate for the quarter, but it would not fully resolve the central medium-term concern.
Q1 revenue increased 6.2%, but foreign exchange contributed approximately 4.5 percentage points. Clear-aligner revenue grew 7.4%, with currency providing a 4.7-point benefit. Meanwhile, clear-aligner volume grew 6.7%, highlighting the offset from discounts and shifts toward lower-priced countries and products. (sec.gov)
This makes Q2’s ASP commentary particularly important. Management expects clear-aligner ASP to be approximately flat both sequentially and year over year, but it previously indicated that full-year ASP could decline 1%–2%.
Investors should distinguish among:
The lower-priced products are not necessarily negative. Zero-AA and limited-refinement products can carry attractive margins because they require less treatment planning, manufacturing and shipping. The ideal outcome is therefore lower ASP from intentional mix, paired with higher volume, better conversion and stable-to-improving margins.
Q1 Systems & Services revenue was $184.1 million, up only 0.9% reported and down 12.1% sequentially. Currency contributed 3.8 percentage points to year-over-year growth, implying underlying weakness. Management attributed this partly to normal Q1 capital-equipment seasonality and a shift toward lower-priced PC configurations, leasing, rentals and certified pre-owned systems. (sec.gov)
Q2 revenue is expected to improve sequentially. Investors should look beyond that easy seasonal hurdle and assess:
The most constructive signal would be growth in new-doctor placements and full systems, rather than a quarter dependent mainly on upgrades or lower-priced configurations.
Align also introduced additional AI-enabled diagnostic, simulation and restorative-planning features shortly before earnings. These reinforce the strategic value of the integrated digital platform, but their near-term revenue impact is likely limited; management’s comments on adoption and monetization will matter more than the announcement itself. (businesswire.com)
Q1’s non-GAAP operating margin of 21.5% was roughly 200 basis points above the company’s initial outlook. Nevertheless, Q2 guidance calls for the same 21.5% margin despite higher expected sequential revenue. Management cited continued investment and a prudent approach toward macroeconomic and Middle East uncertainty. (investor.aligntech.com)
The bigger issue is the full-year target:
Using the midpoint of Q2 revenue guidance and a 21.5% Q2 margin, the full-year target implies an approximate 26% non-GAAP operating margin during the second half. That is achievable given seasonal leverage and restructuring savings, but it is a demanding step-up.
Investors should ask management to bridge the second-half expansion through:
A Q2 margin above 21.5% would improve confidence in the full-year target. A margin miss accompanied by an unchanged 23.7% target would make the second-half assumptions more difficult to underwrite.
Align’s 2025 revenue was approximately $4.035 billion. The current 3%–4% growth outlook implies 2026 revenue of approximately $4.16 billion to $4.20 billion.
Assuming Q2 lands near $1.05 billion, the remaining second-half revenue requirement would imply only low-single-digit growth against the second half of 2025. That suggests management has room to absorb some combination of:
Therefore, a simple guidance reaffirmation would be credible but not especially bullish. A more meaningful positive would be either:
Align entered Q2 with more than $1 billion in cash and planned to repurchase up to an additional $200 million over six months beginning around May 1. Investors should look for the amount completed, average purchase price and management’s remaining U.S. cash flexibility. (sec.gov)
The European Commission opened an investigation concerning Align’s scanner and scan-acceptance policies following a competitor complaint. Align disputes any suggestion of wrongdoing and notes that opening an investigation is procedural rather than a finding on the merits. This is unlikely to affect Q2 numbers materially, but management may face questions regarding potential remedies, legal costs and whether the matter could affect iTero/Invisalign integration in Europe. (businesswire.com)
The recent board-chair transition is unlikely to affect the quarter, but investors may watch for changes in strategic or capital-allocation priorities under new Chairman Kevin Conroy.
The bar for an acceptable Q2 is straightforward: revenue around $1.05 billion, clear-aligner volume above Q1, sequential Systems improvement, a 21.5% non-GAAP margin and maintained full-year guidance.
But the stock’s longer-term direction will depend on more than meeting those targets. Investors need evidence that:
A modest numerical beat without improved U.S. commentary or a credible margin bridge may not be enough. Conversely, evidence of positive North American growth and continued cost leverage could materially strengthen the recovery thesis.